Tevogen Bio Holdings Inc. TVGN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
33/100
Developing

About Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer … Full TVGN analysis →

Competitive advantage assessment

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.23), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.03), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where TVGN ranks in Biotechnology

Tevogen Bio Holdings Inc. ranks #475 of 713 scored companies in Biotechnology by moat score — the top 67%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near TVGN in Biotechnology
# Company Moat score Rating
471 Biomea Fusion, Inc. BMEA 33/100 Developing
472 PMGC Holdings Inc. ELAB 33/100 Developing
473 Lisata Therapeutics, Inc. LSTA 33/100 Developing
474 Candel Therapeutics, Inc. CADL 33/100 Developing
475 Tevogen Bio Holdings Inc. TVGN 33/100 Developing
476 Iterum Therapeutics plc ITRM 33/100 Developing
477 Aligos Therapeutics, Inc. ALGS 33/100 Developing
478 TuHURA Biosciences, Inc. HURA 33/100 Developing
479 Imunon, Inc. IMNN 33/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How TVGN scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 55 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 16 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TVGN's moat

What is Tevogen Bio Holdings Inc.'s moat score?

Tevogen Bio Holdings Inc. (TVGN) scores 33 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #475 of 713 scored companies in Biotechnology, the top 67%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (55/100) and its weakest is Resilience (16/100).

How does Tevogen Bio Holdings Inc. compare with other Biotechnology companies?

Tevogen Bio Holdings Inc. ranks #475 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Candel Therapeutics, Inc. (CADL) at 33 just above it and Iterum Therapeutics plc (ITRM) at 33 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Tevogen Bio Holdings Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Tevogen Bio Holdings Inc.?

The Corporate Default template measures 6 defenses, and TVGN scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (55), Resilience (16), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000